Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Feb 23, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

CDK4/6 Inhibitors Induce Antitumor Immunity

    Cancer Discovery
    |September 3, 2017
    PubMed
    Summary

    Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors boost anti-tumor immunity by increasing immune cell activity and reducing immune suppression. This suggests combining CDK4/6 inhibitors with checkpoint blockers may improve cancer treatment outcomes.

    Area of Science:

    • Oncology
    • Immunology
    • Pharmacology

    Background:

    • CDK4/6 inhibitors are established cancer therapeutics inducing cell-cycle arrest.
    • The immunomodulatory effects of CDK4/6 inhibitors are increasingly recognized.
    • Regulatory T cells (Tregs) contribute to immune evasion in cancer.

    Purpose of the Study:

    • To elucidate the mechanisms by which CDK4/6 inhibitors modulate the tumor immune microenvironment.
    • To investigate the potential of combining CDK4/6 inhibitors with immune checkpoint blockade agents.

    Main Methods:

    • Analysis of immune cell populations and cytokine profiles in preclinical cancer models treated with CDK4/6 inhibitors.
    • Assessment of tumor antigen presentation and T cell responses.

    More Related Videos

    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
    07:36

    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

    Published on: June 12, 2021

    7.7K
    Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
    11:11

    Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

    Published on: January 24, 2020

    11.5K

    Related Experiment Videos

    Last Updated: Feb 23, 2026

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
    09:15

    Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

    Published on: February 24, 2023

    4.1K
    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
    07:36

    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

    Published on: June 12, 2021

    7.7K
    Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
    11:11

    Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

    Published on: January 24, 2020

    11.5K

    Main Results:

    • CDK4/6 inhibition stimulates the production of type III interferons, enhancing tumor antigen presentation.
    • CDK4/6 inhibitors suppress the activity and frequency of regulatory T cells.
    • Combined treatment with checkpoint inhibitors demonstrates synergistic antitumor effects.

    Conclusions:

    • CDK4/6 inhibitors possess significant immunomodulatory properties beyond cell-cycle arrest.
    • The immune-stimulatory and immunosuppressive effects of CDK4/6 inhibitors support their combination with checkpoint blockade for enhanced cancer immunotherapy.